A new study supported by the National Institutes of Health aims to improve gestational diabetes screening and diagnosis by better understanding blood glucose levels throughout pregnancy.
Research led by Dr. Philip Kern was highlighted by the National Institute of Diabetes and Digestive and Kidney Diseases.
LEXINGTON, Ky. (June 2, 2021) – Research led by University of Kentucky endocrinologist and Center for Clinical & Translational Science director Dr. Philip Kern was recently highlighted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in its 2021 Recent Advances & Emerging Opportunities report. The publication conveys important accomplishments resulting from NIDDK-funded research, as well as the enormous promise this research holds for the future.
Kern’s research demonstrated for the first time that a medication called mirabegron, already FDA-approved to treat overactive bladder, improves multiple measures of glucose metabolism in people who are overweight/obese with insulin resistance by inducing beige fat formation in their white adipose fat tissue. The findings uncover a potential new mechanism for treatment of diabetes.
/PRNewswire/ CalciMedica Inc. ("CalciMedica" or the "Company), a clinical-stage biotechnology platform company targeting calcium release-activated calcium.
Researchers at Washington University School of Medicine in St. Louis and Cornell University have collaborated to implant insulin-secreting beta cells grown from human stem cells into mice with diabetes, to normalize their blood sugar.